Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BreakVax Combination Immunotherapy in Triple-Negative Breast Cancer
NCT07762703Phase 2Not yet recruiting
- Sponsor
- BreakBio Corp.
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of BreakVax in triple-negative breast cancer (TNBC), sponsored by BreakBio Corp.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BreakVax
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07762703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762703.